Arcturus Therapeutics (ARCT) Stock: Buy, Sell, or Hold?
ARCT - Arcturus Therapeutics Holdings Inc. Common Stock
$14.73
0.75 (5.36%)
â˛
5d:
-5.33%
30d:
+93.82%
90d:
+111.33%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ARCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ARCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ARCT is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ARCT is currently trading at $14.73, which is considered slightly high relative to its 30-day fair value range of $7.52 to $15.47.
Technical Outlook: Technically, ARCT is in a uptrend. Immediate support is located at $13.12, while resistance sits at $17.75. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ARCT scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.30 (+51.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARCT is in a uptrend. Immediate support is located at $13.12, while resistance sits at $17.75. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: ARCT scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.30 (+51.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.52 -
$15.47
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- BULLISH: Trading 51.4% below Wall St target ($22.30)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.52 -
$15.47
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$13.12
Resistance Level
$17.75
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.08
Wall Street Target
$22.30
(+51.4%)
Revenue Growth (YoY)
-89.5%
Share & Embed Analysis
Last updated: September 13, 2026 4:30 AM ET
Data refreshes hourly during market hours. Next update: 5:30 AM
Data refreshes hourly during market hours. Next update: 5:30 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
